Efficacy of Abiraterone and Enzalutamide in Pre- and Postdocetaxel Castration-Resistant Prostate Cancer: A Trial-Level Meta-Analysis

Table 1

All studies included in analysis.

Author/study	PMID	Clinical trial code		Treatment	Race	Age	Gleason score ≥ 8	Baseline PSA; (median)	PSA decline; ≥ 50%
Thortzen et al.	26971191		45	AX	White	71.3	60%	156	51%
Poon et al.	27001043		58	AX	Asian	77.0	28%	212	62%
Suzman et al.	25053178		30	AX	White	70.6	48%	192	34%
Kim et al.	25336698		39	AX	White	71.0		48.5	41%
COU-AA-302	23228172	NCT00887198	546	AX	White	70.5			29%
Yamasaki et al.	26722066		51	EX	Asian	74.0	78%	11.2	63%
Higano and Crawford	25698064		65	EX	White	68.0		35	63%
TERRAIN	26774508	NCT01288911	184	EX	White	70.3	55%	21	82%
STRIVE	26811535	NCT01664923	198	EX	White	72.0	51%	11	81%
PREVAIL	25888263	NCT01212991	872	EX	White	71.3	51%	54.1	78%
Kwak et al.	25099185		82	DA	Asian	71.0	74%	124.3	49%
Ferraldeschi et al.	25454616		57	DA	White	66.0	41%	155	32%
COU-AA-301	23142059	NCT00638690	797	DA	White	69.0	51%	27	38%
Praet et al.	26850781		368	DA	White	73.0		103	37%
Poon et al.	27001043		52	DA	Asian	66.0	56%	191	50%
Thortzen et al.	26971191		28	DA	White	70.7	71%	169	18%
Caffo et al.	24988879		265	DA	White	73.0	51%	86	50%
Burgio et al.	24999168		103	DA	White	74.0	53%	32.5
Ferraldeschi et al.	25454616		87	DA	White	69.0	55%	237	43%
Qu et al.	27489290		81	DA	White		49%	16.4
Conteduca et al.	27434372		193	DE	White	73.1			51%
Yamasaki et al.	26722066		40	DE	Asian		83%	23	44%
Higano and Crawford	25698064		75	DE	White	68.0		64	53%
AFFIRM	22894553	NCT00974311	800	DE	White	68.8	50%	107.7	54%

The studies that provided two cohorts for our analyses are denoted () and correspond to those in Figures 2 and 3. Race is the predominant proportion within each cohort and age is either a mean or median measure. Blank cells indicate a lack of reporting in that category.